Secukinumab in the Treatment of Hidradenitis Suppurativa

Hidradenitis Suppurativa | COSENTYX® (secukinumab)

COSENTYX (secukinumab) is the first FDA-approved medicine of its kind to treat adults with moderate to severe hidradenitis suppurativa (HS).

Secukinumab in the treatment of hidradenitis suppurativa - PubMed

The IL-17 pathways are involved in the pathophysiology of many inflammatory skin conditions, including hidradenitis suppurativa. Secukinumab ...

Secukinumab in moderate-to-severe hidradenitis suppurativa ...

Few therapeutic options exist for the treatment of moderate-to-severe hidradenitis suppurativa. To date, adalimumab, a TNFα inhibitor, is the ...

Secukinumab in moderate-to-severe hidradenitis suppurativa ...

Interpretation: When given every 2 weeks, secukinumab was clinically effective at rapidly improving signs and symptoms of hidradenitis ...

Secukinumab in patients with moderate-to-severe hidradenitis ...

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with a substantial disease burden. Secukinumab has previously been reported to ...

FDA approves Novartis Cosentyx® as the first new biologic ...

FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade · Cosentyx ...

Secukinumab treatment of hidradenitis suppurativa: questions remain

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, ...

Treatment with secukinumab in patients with severe HS | CCID

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study ... Recently (31 October 2023) FDA approves ...

Full article: Secukinumab in the Treatment of Hidradenitis Suppurativa

Secukinumab has demonstrated promising results in the treatment of hidradenitis suppurativa in the phase III SUNSHINE and SUNRISE clinical trials.

Secukinumab Gains FDA Approval to Treat Hidradenitis Suppurativa

Secukinumab Gains FDA Approval to Treat Hidradenitis Suppurativa ... The approval of secukinumab is the second approved biologic to treat ...

An evaluation of secukinumab for the treatment of moderate-to ...

Secukinumab is the first approved anti-IL-17A therapy with documented efficacy in HS. The reported efficacy, based on HiSCR achievement, mounts to 45% of the ...

Secukinumab for treating moderate to severe hidradenitis suppurativa

Overview. Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in ...

Secukinumab in the treatment of moderate to severe hidradenitis ...

To the Editor: Hidradenitis suppurativa (HS) is an inflammatory skin disease that is challenging to treat. Patients with HS have imbalances in the T-helper. 17 ...

Patients with hidradenitis suppurativa experienced sustained ...

Results at Week 16 showed a significantly higher proportion of patients achieved a Hidradenitis Suppurativa Clinical Response (HiSCR) when ...

Secukinumab in moderate-to-severe hidradenitis suppurativa ...

Secukinumab, a fully human monoclonal antibody that selectively neutralises interleukin (IL)-17A, has been reported to improve clinical signs and symptoms of ...

European Commission Approves Secukinumab for Hidradenitis ...

The European Commission has approved secukinumab (Cosentyx; Novartis) for the treatment of hidradenitis suppurativa (HS) in adults with moderate to severe ...

Short-Term Effectiveness, Safety, and Potential Predictors of ...

To conclude, secukinumab can be considered a safe and effective treatment option in patients with severe hidradenitis suppurativa. There are ...

Secukinumab in the treatment of hidradenitis suppurativa.

The IL-17 pathways are involved in the pathophysiology of many inflammatory skin conditions, including hidradenitis suppurativa. Secukinumab ...

Secukinumab in the treatment of moderate to severe hidradenitis ...

Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial

Secukinumab and Bimekizumab for Hidradenitis Suppurativa

A dual IL-17A and IL-17F pathway-targeting biologic, bimekizumab was associated with significantly improved odds of treated patients achieving ...